Letters
Ebola treatments
Ebola treatments: trials stopped early for benefit tend to overestimate the effects of the intervention
BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l5789 (Published 01 October 2019) Cite this as: BMJ 2019;367:l5789- David L Streiner, emeritus professor
- McMaster University, St Joseph’s Healthcare, Mountain Campus, Hamilton, Ontario, Canada L8N 3K7
- streiner{at}mcmaster.ca
A recent news item in The BMJ1 reported that a trial of the antiviral vaccines mAB114 and REGN-EB3 was ended prematurely because it met early stopping criteria for effectiveness. This is encouraging for patients with Ebola, given its high mortality rate, and it is understandable that healthcare workers would want to get these drugs to patients as rapidly …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.